戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tropism changes or reduced susceptibility to vicriviroc.
2                       Among 90 recipients of vicriviroc, a significantly (P< .001) greater mean reduc
3 rn associated with reduced susceptibility to vicriviroc, although numerous changes were observed in t
4                                              Vicriviroc, an investigational CCR5 inhibitor, demonstra
5 ve to most other CCR5 antagonists, including vicriviroc and aplaviroc.
6 nancies occurred in 6 subjects randomized to vicriviroc and in 2 to placebo.
7 used in HIV, [small molecules (maraviroc and vicriviroc) and a humanized mAb (leronlimab)], are now b
8 nces in this ratio were found for maraviroc, vicriviroc, aplaviroc, Sch-C, TAK652, and TAK779.
9         Five clinical candidates: maraviroc, vicriviroc, aplaviroc, TAK-779, and TAK-220 were used to
10                                              Vicriviroc at 5, 10, or 15 mg or placebo was added to th
11 -1-infected, treatment-experienced patients, vicriviroc demonstrated potent virologic suppression thr
12            The CCR5 antagonists maraviroc or vicriviroc, developed to block CCR5 HIV coreceptor funct
13 y inhibitors maraviroc, AD101, CMPD 167, and vicriviroc dramatically increases receptor stability.
14 ses that exhibited reduced susceptibility to vicriviroc, envelope clones were phenotypically and geno
15 evel (log(10) copies/mL) were greater in the vicriviroc groups (-0.87 and -1.51 [5 mg], -1.15 and -1.
16                       Further development of vicriviroc in treatment-experienced patients is warrante
17  a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficie
18                                              Vicriviroc is a C-C motif chemokine receptor 5 (CCR5) an
19                    Reduced susceptibility to vicriviroc, manifested as decreases in the maximum perce
20  These derivatives retained activity against vicriviroc-resistant HIV-1s, but did not show activity a
21 ximal responses for aplaviroc, maraviroc and vicriviroc suggests that these modulators have minimal e
22                          The relationship of vicriviroc to malignancy is uncertain.
23                                   Twenty-six vicriviroc-treated subjects experienced virological fail
24 rom a phase IIb study of the CCR5 antagonist vicriviroc (VCV) and identified one individual with HIV-
25 uninfected women, evaluated 2 VRs containing vicriviroc (VCV) and MK-2048.
26                                              Vicriviroc (VCV) is a CCR5 antagonist that blocks the vi
27                                              Vicriviroc (VCV) is a CCR5 antagonist with nanomolar act
28                                              Vicriviroc (VCV) is a chemokine (C-C motif) receptor 5 (
29                                              Vicriviroc (VCV) is a small-molecule CCR5 coreceptor ant
30 ected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, du
31  antagonist resistance during treatment with vicriviroc (VCV), an investigational small-molecule CCR5
32 evaluated VRs containing MK-2048 (30 mg) and vicriviroc (VCV, 182 mg), alone or in combination, and p
33       Small-molecule CCR5 inhibitors such as vicriviroc (VVC) and maraviroc (MVC) are allosteric modu
34 85.16, to the small molecule CCR5 inhibitor, vicriviroc (VVC).